Clinical trial
Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
NCT05472623
Study timeline
Study start (actual)2023-03-21Date precision: day
Registry last updated2025-09-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Resectable Non-Small Cell Lung Cancerunresolved
Interventions
AdagrasibDRUG · verified · RxNorm: adagrasib
Adagrasib/NivolumabCOMBINATION_PRODUCT
Sponsors & collaborators
Mirati Therapeutics Inc.collaborator
Bristol-Myers Squibbcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05472623 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.